Core Viewpoint - The company, Yidu Tech (02158), demonstrates strong confidence in its long-term value and the prospects of the AI healthcare industry through its ongoing share buyback program, having repurchased 322,000 shares at approximately HKD 5.99 per share, totaling nearly HKD 2 million on February 27 [1] Group 1: Share Buyback Activity - Yidu Tech has completed 19 share buybacks this year, with a total expenditure exceeding HKD 76 million [1] - The buyback actions are seen as a consistent strategy to reinforce the company's commitment to its value and the AI healthcare sector [1] Group 2: Industry Insights - According to a report by Zhonghang Securities, domestic and international healthcare companies are increasingly investing in AI products and services across various areas, including medical imaging, clinical decision support, precision medicine, health management, medical information technology, drug development, and medical robotics [1] - AI is evolving from a "technical assistance" role to becoming a core driver of "value reshaping" and "efficiency revolution" in the healthcare industry, with its commercial value permeating from research to clinical, payment, and patient levels [1] Group 3: Business Developments - Yidu Tech has made significant innovations, including the internal testing of its clinical evidence-based intelligent system "Yidu Zhixun" [1] - A project supported by Yidu Tech for infectious disease monitoring and early warning in Hainan Free Trade Port has been recognized at the national level, being included in the "2025 Data Element ×" competition award project case collection [1]
医渡科技(02158)2月27日再回购近200万港元 获中航证券重点推荐